
Quarterly ResultAug 13, 2026, 04:19 PM
Inhibrx Q2 Net Loss $36.7M; Ozekibart BLA Accepted by FDA
AI Summary
Inhibrx Biosciences reported its second quarter 2026 financial results, including a net loss of $36.7 million. The company announced that the FDA accepted its Biologics License Application (BLA) for ozekibart in conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027. Additionally, Inhibrx secured an amendment to its loan agreement with Oxford Finance LLC, providing an additional $325.0 million in gross proceeds, with $100.0 million already funded. The company also provided updates on its clinical programs, including plans to announce INBRX-106 PFS data in Q3 2026 and initiate new ozekibart Phase 1 cohorts.
Key Highlights
- FDA accepted BLA for ozekibart in conventional chondrosarcoma, with PDUFA date of April 14, 2027.
- Secured $325.0M additional gross proceeds from Oxford loan amendment; $100.0M funded.
- Net loss for Q2 2026 was $36.7 million, or $2.34 per share.
- Cash and cash equivalents totaled $219.5 million as of August 6, 2026.
- R&D expenses increased to $23.9 million in Q2 2026 from $22.3 million in Q2 2025.
- G&A expenses rose to $8.3 million in Q2 2026 from $6.4 million in Q2 2025.
- Plans to announce INBRX-106 PFS data from Phase 2 trial in Q3 2026.
- Initiated two new ozekibart Phase 1 cohorts in colorectal cancer.
Price Impact
More from INBX